Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLID.L Regulatory News (LID)

  • There is currently no data for LID

LiDCO Extends Collaboration With BD

16 Apr 2009 07:00

RNS Number : 6366Q
LiDCO Group Plc
15 April 2009
 



Press Release 

16 April 2009

LiDCO Group Plc

("LiDCO" or "the Company")

LiDCO extends collaboration with BD

LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, today has extended its exclusive collaboration with BD (Becton, Dickinson and Company)a leading global medical technology company dedicated to helping all people live healthy lives (see www.bd.com).

In June 2007, LiDCO signed an exclusive UK marketing collaboration with Becton, Dickinson U.K. LimitedLiDCO today announces the expansion of this exclusive collaboration with BD. Under the amended and restated terms of the agreement, LiDCO and BD will extend their exclusive marketing collaboration to include additional territories. The collaboration provides that BD Medical - Medical Surgical Systems regional sales teams will provide sales and marketing support for LiDCO products in territories additional to the UK. This marketing collaboration will result in an enhanced product offering for BD's customers as well as superior sales coverage for both LiDCO and LiDCO's network of distributors. 

In a separate agreement, LiDCO have entered an exclusive distribution and sales relationship for the LiDCOrapid Monitor with BD in Japan. This relationship will result in an enhanced product offering for BD customers, as well as improved access to LiDCO's technology by Japanese clinicians and patients. 

Dr Terry O'Brien, Chief Executive of LiDCO, commenting on the agreements stated: "This licensing arrangement in Japan and expansion of our marketing collaboration with a major corporation of the stature of BD further enhances our capabilities to provide our acute care customers with the best possible products and services to improve outcomes and reduce complications such as infections. We are very pleased to share a commitment with BD towards expanding access to innovative technologies that improve outcomes in the critically ill." 

Hideyuki Ashikaga, President, BD in Japan stated:

"BD designs and markets innovative products that address significant healthcare problems and deliver demonstrably higher benefits to patients, healthcare workers and researchers. Collaborating with LiDCO, an innovative company in an important healthcare market, will reinforce our capabilities to serve that market, in line with our corporate purpose of 'Helping all people live healthy lives'".

- ENDS -

For more information please contact:

LiDCO Group Plc

Terry O'Brien - Chief Executive

John Rowland - Company Secretary

Tel: +44 (0)20 7749 1500

www.lidco.com

FinnCap

Geoff Nash/ Stephen Norcross/

Marc Young 

+44 (0)20 7600 1658

www.finncap.com 

Media enquiries

Abchurch Communications

Heather Salmond / Stephanie Cuthbert / Simone Alves 

+44 (0)20 7398 7728

www.abchurch-group.com

About LiDCO Group Plc

LiDCO is a leading supplier of minimally invasive hemodynamic monitoring equipment and disposables. These are used primarily for the management of hospital patients requiring critical care or at major cardiovascular risk. LiDCO's computer-based technology significantly reduces the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. LiDCO is based in the UK and its shares are traded on AIM. For more information please see www.lidco.com.

The Company's manufacturing facility is in Hoxton, London, and its current products are:

* LiDCOplus is a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%)

* LiDCOrapid: our new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management at the point of care. The monitor features many clinical benefits. These enable acute-care physicians to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being during and after surgery. 

Early and rapid warning of change

Clear indication of therapeutic route: fluid or drug

Quantification of hemodynamic response, particularly stroke volume

Permits more effective delivery of fluids - the right amount at the right time

Advanced hemodynamic care has been shown to:

- Contribute to reduced morbidity and complications

- Reduce length of stay

- Reduce overall cost of care

* LiDCO single-patient-use disposables used in conjunction with the LiDCOplus and LiDCOrapid Monitors. 

LiDCOview: an easy-to-use graphical display of historical LiDCOplus hemodynamic data. Both clinical researchers and routine users can view beat-to-beat hemodynamic data collected with the LiDCOplus. LiDCOviewSE is the standard version of this tool and is available for free, allowing anyone to download and access data from the LiDCOplus. LiDCOviewPRO is the Professional version, allowing users to analyse, export and report the LiDCOplus data. A free trial of LiDCOviewPRO is available for evaluation purposes prior to purchase

LiDCO Distribution Network:

The Company sells direct to hospitals in the UK, and elsewhere predominantly through a worldwide network of specialty critical care and anesthesia distributors.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCIAMFTMMJBBML
Date   Source Headline
1st May 20147:00 amRNSPositive haemodynamic monitoring study
29th Apr 20147:00 amRNSFinal Results
7th Apr 20147:00 amRNSNotice of Results and Investor briefing
17th Mar 20147:00 amRNSLaunch of New Version of LiDCOrapid software
12th Mar 20147:00 amRNSResults of cost effectiveness trial
28th Feb 201411:34 amRNSTotal Voting Rights
12th Feb 20147:00 amRNSTrading update and notice of results
7th Feb 20149:21 amRNSHolding(s) in Company
28th Jan 20143:01 pmRNSHolding(s) in Company
27th Jan 20144:10 pmRNSBlocklisting Application
20th Jan 20149:54 amRNSReplacement:Anaesthetists guidelines supports LID
20th Jan 20147:00 amRNSAnaesthetists guidelines supports LiDCO
18th Oct 20134:04 pmRNSExercise of Share Options
1st Oct 20137:00 amRNSHalf Yearly Report
26th Sep 20137:00 amRNSNotice of Patent Acceptance
20th Sep 20137:00 amRNSInvestor Results Briefing
6th Sep 20134:33 pmRNSHolding(s) in Company
4th Sep 20137:00 amRNSFDA clearance
20th Aug 20137:00 amRNSTrading update
13th Aug 201312:11 pmRNSNotification of major interest in shares
12th Jun 201311:43 amRNSResults of Annual General Meeting
12th Jun 20137:00 amRNSAGM Statement
10th Jun 201310:08 amRNSNotification of major interest in shares
5th Jun 20137:00 amRNSLiDCOrapid in successful recovery programme
31st May 20139:50 amRNSGrant of Share Options
17th May 20133:30 pmRNSNotice of AGM and posting of Annual Report
9th May 20137:00 amRNSLiDCOrapidv2 incorporated in NHS Foundation Trust
8th May 20133:51 pmRNSExercise of Share Options
23rd Apr 20137:00 amRNSPreliminary Results
26th Mar 20137:00 amRNSUS FDA clears for sale LiDCOrapidv2
15th Mar 20137:00 amRNSGrant of LiDCOrapid user interface patent in Japan
22nd Feb 20133:25 pmRNSDirector/PDMR Shareholding
21st Feb 201312:45 pmRNSExercise of Share Options
7th Feb 20137:03 amRNSLaunch and first sales of the LiDCOrapid v2
5th Feb 20137:00 amRNSTrading Update and Notice of Preliminary Results
17th Dec 20127:00 amRNSTrading Statement
29th Nov 20122:00 pmRNSTR-1 Notification of Major Interest in Shares
27th Nov 20127:00 amRNSExercise of Share Options
27th Nov 20127:00 amRNSProtocol using LiDCOrapid improves outcomes
23rd Nov 20127:00 amRNSLiDCOrapid v2 satisfies NICE recommendation
13th Nov 20127:00 amRNSFundraising to raise £2.35 million
23rd Oct 20127:00 amRNSInterim Results
15th Oct 20123:00 pmRNSExercise of Share Options
15th Oct 20127:00 amRNSPremier of LiDCOrapid v2 with Unity Software
14th Sep 20123:20 pmRNSNotice of Interim Results
3rd Sep 201212:00 pmRNSExercise of Share Options
23rd Aug 20127:00 amRNSTrading update and resignation of Director
3rd Aug 20127:00 amRNSNihon Kohden appointed as distributor in Japan
11th Jul 20127:00 amRNSReimbursement approval received in Japan
4th Jul 20123:05 pmRNSGrant of Share Option

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.